Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of BioLineRx from a hold rating to a buy rating and set a $1.00 price objective on the stock in a research report on Thursday, June 2nd. Maxim Group reaffirmed a hold rating and issued a $1.00 price objective on shares of BioLineRx in a research report on Wednesday, September 7th. Finally, Roth Capital reaffirmed a buy rating and issued a $7.00 price objective on shares of BioLineRx in a research report on Sunday, August 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. BioLineRx presently has an average rating of Buy and an average price target of $2.68.
BioLineRx (NASDAQ:BLRX) opened at 1.16 on Friday. The firm has a 50-day moving average of $0.95 and a 200 day moving average of $0.92. The company’s market capitalization is $65.45 million. BioLineRx has a 52-week low of $0.71 and a 52-week high of $1.73.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.02. Equities analysts predict that BioLineRx will post ($0.26) earnings per share for the current fiscal year.
An institutional investor recently raised its position in BioLineRx stock. Menta Capital LLC increased its stake in BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned about 0.18% of BioLineRx worth $101,000 at the end of the most recent quarter. 12.46% of the stock is owned by institutional investors.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.